Form 4: RAPT Therapeutics CFO Acquires 642,000 Stock Options

RAPT Therapeutics' Chief Financial Officer, Rodney Young, acquired 642,000 employee stock options on January 30, 2025.

Summary

• Rodney Young, the Chief Financial Officer of RAPT Therapeutics, acquired 642,000 employee stock options.
• The options were granted on January 30, 2025, at an exercise price of $1.14 per share.
• The options vest monthly over four years, starting on January 1, 2025, with 1/48th of the shares vesting each month.
• The options expire on January 29, 2035.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally positive for aligning management with shareholder interests. It is not a major event, but it is a positive indicator of management's commitment.

Positives

• The grant of stock options to the CFO aligns his interests with the long-term success of the company.
• The vesting schedule encourages continued service and performance from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating executives in the biotech industry.
• The vesting schedule of 1/48th monthly over four years is a typical vesting structure for stock options.
• The exercise price of $1.14 is specific to RAPT Therapeutics and its current valuation.

Stakeholder Impact

• The stock option grant may have a minor positive impact on shareholder sentiment as it aligns management's interests with the company's performance.

Key Dates

Keywords

stock options, insider trading, executive compensation, RAPT Therapeutics, Rodney Young, CFO